Collegium Pharmaceutical will acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with up to $135 million in potential milestone payments. The deal adds a marketed ADHD product to Collegium's portfolio, likely accelerating near-term revenue opportunities for Collegium while introducing integration and milestone-related execution risk.
Collegium Pharmaceutical will acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with up to $135 million in potential milestone payments. The deal adds a marketed ADHD product to Collegium's portfolio, likely accelerating near-term revenue opportunities for Collegium while introducing integration and milestone-related execution risk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
